The use of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has significantly improved progression-free survival in lung cancer patients harboring activating EGFR mutations; however, it is still difficult to achieve a cure for lung cancer, particularly in patients with advanced-stage disease [1], [2]. This evidence concerns the gene EGFR and lung cancer.